Clinical Trials
61 trialsNCT02517918 2025-06-08
METZOLIMOS
Institut Bergonié
Phase 1 Completed
NCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00330759 2022-11-07
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Amgen
Phase 3 Completed
NCT00566618 2022-02-25
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01951586 2021-10-25
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen
Phase 2 Completed
NCT00127205 2021-07-02
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
SWOG Cancer Research Network
Phase 3 Completed
NCT00622505 2021-05-26
Z-MARK
Novartis
Phase 4 Completed
NCT00058188 2020-12-08
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Northwestern University
Phase 3 Terminated
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00295867 2020-05-12
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT01409811 2020-05-08
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
City of Hope Medical Center
Phase NA Terminated
NCT00305695 2020-03-24
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
GOG Foundation
Phase 2 Completed
NCT00213980 2019-11-27
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT01772719 2019-11-18
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
University of Louisville
Phase NA Terminated
NCT00436917 2019-09-11
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
Mayo Clinic
Phase NA Completed
NCT01205646 2019-04-12
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01194440 2018-09-12
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00321620 2018-08-29
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00399802 2018-08-16
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00265200 2018-03-05
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
University of Louisville
Phase 2 Terminated
NCT00329797 2017-11-29
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01204203 2017-05-24
UAB0901
University of Alabama at Birmingham
Phase 2 Completed
NCT00577642 2017-03-10
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Massachusetts General Hospital
Phase 2 Completed
NCT00321932 2017-03-09
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
University of Minnesota
Phase 2 Completed
NCT01920568 2017-01-16
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
GlaxoSmithKline
Phase 3 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02739594 2016-07-22
COMPARE
Hoffmann-La Roche
Phase 3 Terminated
NCT00903162 2016-04-18
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00966992 2015-09-09
Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00375505 2015-09-07
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
Novartis
Phase 3 Completed
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00172042 2015-05-04
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 3 Completed
NCT00333229 2014-11-25
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Novartis
Phase 4 Terminated
NCT00320710 2014-08-22
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Novartis
Phase 3 Completed
NCT00972959 2014-08-05
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
University of Athens
Phase 2 Completed
NCT00742924 2014-07-04
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Children's Oncology Group
Phase 1 Completed
NCT01129336 2014-05-20
MACS1295
Novartis
Phase 4 Completed
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed
NCT00712985 2014-04-24
CTIBL
Milton S. Hershey Medical Center
Phase 3 Completed
NCT00215943 2014-04-17
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Phase 3 Terminated
NCT00050011 2014-03-21
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Novartis
Phase 3 Completed
NCT00352846 2013-07-02
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00558272 2013-05-27
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AstraZeneca
Phase 2 Completed